References
- ChiangCEWangTDLiYH2010 Guideline of the Taiwan Society of Cardiology for the management of hypertensionJ Formos Med Assoc201010974077320970072
- LewingtonSClarkeRQizilbashNAge-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studiesLancet20023601903191312493255
- KannelWBRisk stratification in hypertension: New insight from the Framingham StudyAm J Hypertens2000131 Pt 2S3S10
- DeedwaniaPEvolving treatment options for prevention of cardiovascular events in high-risk hypertensive patientsJ Clin Hypertens20079883888
- NealBMacMahonSChapmanNEffects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists’ CollaborationLancet20004212061252
- KannelWBHazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failureCardiovasc Drugs Ther199711Suppl 11992129211012
- KemplerPLearning from large cardiovascular clinical trials: Classical cardiovascular risk factorsDiabetes Res Clin Pract200568Suppl 1S43S4715955374
- StamlerJVaccaroONeatonJDDiabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TrialDiabetes Care1993164344448432214
- ChobanianAVBakrisJLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure: The JNC 7 ReportJAMA20032892560257112748199
- ManciaGDe BackerGDominiczakA2007 ESH-ESC Guideline for the management of arterial hypertensionBlood Press20071613513217846925
- The Heart Outcomes Prevention Evaluation Study InvestigatorsEffects of an angiotensin-concerting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patientsN Engl J Med200034214515310639539
- DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenololLancet2002359995100311937178
- DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcome Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicenter randomized controlled trialLancet200536689590616154016
- ADVANCE Collaborative GroupEffects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE Trial): A randomized controlled trialLancet200737082984017765963
- The ONTARGET InvestigatorsTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med20083581547155918378520
- The TRANSCEND InvestigatorsEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomized controlled trialLancet20083721174118318757085
- The ACCOMPLISH Trial InvestigatorsBenazapril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med20083592417242819052124
- StaessenJARichartTWangZImplications of recently published trials of blood pressure lowering drugs in hypertensive or high-risk patientsHypertension20105581983120212274
- ZanchettiAGrassiGManciaGWhen should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisalJ Hypertens20092792393419381107
- The ACCORD Study InvestigatorsEffects of intensive blood-pressure control in type 2 diabetes mellitusN Engl J Med20103621575158520228401
- The VALUE Trial InvestigatorsOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trialLancet20043632022203115207952
- GaddamKKOparilSRenin inhibition: Should it supplant ACE inhibitors and ARBS in high risk patients?Curr Opin Nephrol Hypertens20081748449018695389
- CagnoniFNjweCANZaninelliABlocking the RAAS at different levels: An update on the use of the direct renin inhibitors alone or in combinationVasc Health Risk Manage20106549559
- FeldmanDLNew insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal diseaseHypertens Res20103327928720203685
- BrownMJMcInnesGTPapstCCAliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): A randomized, parallel-group trialLancet201137731232021236483